Comparative proteomic analysis of human leukemic cells with and without inducible expression of leukemogenic AML1-ETO protein

Chinese Journal of Physiology

Volumn 49, Issue 4, 2006, Pages 182-191

  Zhang, Lei ^a   Wang, Li Shun ^a,b   Xu, Ying ^b   Xia, Li ^a   Chen, Wen Li ^a   Zheng, Ying ^a   Chen, Guo Qiang ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

AML1 ETO; Leukemia; MAT1; MORG1; Proteomics

Indexed keywords

AML1 ETO FUSION PROTEIN, HUMAN; AML1-ETO FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEOME; TRANSCRIPTION FACTOR RUNX1; TUMOR PROTEIN;

ARTICLE; COMPARATIVE STUDY; GENE EXPRESSION; HUMAN; LEUKEMIA; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE EXPRESSION; HUMANS; LEUKEMIA; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEOME;

EID: 34447569757     PISSN: 03044920     EISSN: 26660059     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ahn, M.Y., Huang, G., Bae, S.C., Wee, H.J., Kim, W.Y. and Ito, Y. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ ETO. Proc. Natl. Acad. Sci. USA. 95: 1812-1817, 1998.
2. Alcalay, M., Meani, N., Gelmetti, V., Fantozzi, A., Fagioli, M., Orleth, A., Riganelli, D., Sebastiani, C., Cappelli, E., Casciari, C., Sciurpi, M.T., Mariano, A.R., Minardi, S.P., Luzi, L., Muller, H., Di Fiore, P.P., Frosina, G. and Pelicci, P.G. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J. Clin. Invest. 112: 1751-1761, 2003.
3. Amann, J.M., Nip, J., Strom, D.K., Lutterbach, B., Harada, H., Lenny, N., Downing, J.R., Meyers, S. and Hiebert, S.W. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligo-merization domain. Mol. Cell. Biol. 21: 6470-6483, 2001.
4. Behre, G., Zhang, P., Zhang, D.E. and Tenen, D.G. Analysis of the modulation of transcriptional activity in myelopoiesis and leukemogenesis. Methods 17: 231-237, 1999.
5. Biggs, J.R., Zhang, Y., Peterson, L.F., Garcia, M., Zhang, D.E. and Kraft, A.S. Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. Mol. Cancer Res. 3: 391-401, 2005.
6. Burel, S.A., Harakawa, N., Zhou, L., Pabst, T., Tenen, D.G. and Zhang, D.E. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol. Cell. Biol. 21: 5577-5590, 2001.
7. Chiaramonte, R., Basile, A., Tassi, E., Calzavara, E., Cecchinato, V., Rossi, V., Biondi, A. and Comi, P. A wide role for NOTCH1 signaling in acute leukemia. Cancer Lett. 219: 113-120, 2005.
8. Fliegauf, M., Stock, M., Berg, T. and Lubbert, M. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO. Oncogene 23: 9070-9081, 2004.
9. Giglia-Mari, G., Coin, F., Ranish, J.A., Hoogstraten, D., Theil, A., Wijgers, N., Jaspers, N.G., Raams, A., Argentini, M., van der Spek, P.J., Botta, E., Stefanini, M., Egly, J.M., Aebersold, R., Hoeijmakers, J.H. and Vermeulen, W. A new, tenth subunit of TFIIH is responsible for the DNA repair syndrome trichothiodystrophy group A. Nat. Genet. 36: 714-719, 2004.
10. Heidenreich, O., Krauter, J., Riehle, H., Hadwiger, P., John, M., Heil, G., Vornlocher, H.P. and Nordheim, A. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 101: 3157-3163, 2003.
11. Hiebert, S.W., Lutterbach, B. and Amann, J. Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12; 21), and inv(16) fusion proteins. Curr. Opin. Hematol. 8: 197-200, 2001.
12. Jiang, Y., Xue, Z.H., Shen, W.Z., Du, K.M., Yan, H., Yu, Y., Peng, Z.G., Song, M.G., Tong, J.H., Chen, Z., Huang, Y., Lubbert, M. and Chen, G.Q. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments tran-scriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia 19: 1239-1247, 2005.
13. Kurokawa, M. and Hirai, H. Role of AML1/Runx1 in the pathogen-esis of hematological malignancies. Cancer Sci. 94: 841-846, 2003.
14. Kurokawa, M., Tanaka, T., Tanaka, K., Ogawa, S., Mitani, K., Yazaki, Y. and Hirai, H. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Oncogene 12: 883-892, 1996.
15. Look, A.T. Oncogenic transcription factors in the human acute leukemias. Science 278: 1059-1064, 1997.
16. Lutterbach, B., Westendorf, J.J., Linggi, B., Patten, A., Moniwa, M., Davie, J.R., Huynh, K.D., Bardwell, V.J., Lavinsky, R.M., Rosenfeld, M.G., Glass, C., Seto, E. and Hiebert, S.W. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol. Cell. Biol. 18: 7176-7184, 1998.
17. Mao, S., Frank, R.C., Zhang, J., Miyazaki, Y. and Nimer, S.D. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. Mol. Cell. Biol. 19: 3635-3644, 1999.
18. Mori, H., Colman, S.M., Xiao, Z., Ford, A.M., Healy, L.E., Donaldson, C., Hows, J.M., Navarrete, C. and Greaves, M. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Natl. Acad. Sci. USA. 99: 8242-8247, 2002.
19. Okuda, T., van Deursen, J., Hiebert, S.W., Grosveld, G. and Downing, J.R. AML1, the target of multiple chromosomal translo-cations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84: 321-330, 1996.
20. Peterson, L.F. and Zhang, D.E. The 8;21 translocation in leukemogenesis. Oncogene 23: 4255-4262, 2004.
21. Puccetti, E., Obradovic, D., Beissert, T., Bianchini, A., Washburn, B., Chiaradonna, F., Boehrer, S., Hoelzer, D., Ottmann, O.G., Pelicci, P.G., Nervi, C. and Ruthardt, M. AML-associated translo-cation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res. 62: 7050-7058, 2002.
22. Rhoades, K.L., Hetherington, C.J., Rowley, J.D., Hiebert, S.W., Nucifora, G., Tenen, D.G. and Zhang, D.E. Synergistic up-regula-tion of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc. Natl. Acad. Sci. USA. 93: 11895-11900, 1996.
23. Schwieger, M., Lohler, J., Friel, J., Scheller, M., Horak, I. and Stocking, C. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J. Exp. Med. 196: 1227-1240, 2002.
24. Shimada, H., Ichikawa, H. and Ohki, M. Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis. Leukemia 16: 874-885, 2002.
25. Steffen, B., Serve, H., Berdel, W.E., Agrawal, S., Linggi, B., Buchner, T., Hiebert, S.W. and Muller-Tidow, C. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia. Proc. Natl. Acad. Sci. USA. 100: 8448-8453, 2003.
26. Tanaka, K., Tanaka, T., Kurokawa, M., Imai, Y., Ogawa, S., Mitani, K., Yazaki, Y. and Hirai, H. The AML1/ETO(MTG8) and AML1/ Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1. Blood 91: 1688-1699, 1998.
27. Tanaka, T., Kurokawa, M., Ueki, K., Tanaka, K., Imai, Y., Mitani, K., Okazaki, K., Sagata, N., Yazaki, Y., Shibata, Y., Kadowaki, T. and Hirai, H. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol. Cell. Biol. 16: 3967-3979, 1996.
28. Tassan, J.P., Jaquenoud, M., Fry, A.M., Frutiger, S., Hughes, G.J. and Nigg, E.A. In vitro assembly of a functional human CDK7-cyclin H complex requires MAT1, a novel 36 kDa RING finger protein. EMBO. J. 14: 5608-5617, 1995.
29. Tenen, D.G. Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer. 3: 89-101, 2003.
30. Tenen, D.G., Hromas, R., Licht, J.D. and Zhang, D.E. Transcription factors, normal myeloid development, and leukemia. Blood 90: 489-519, 1997.
31. Vangala, R.K., Heiss-Neumann, M.S., Rangatia, J.S., Singh, S.M., Schoch, C., Tenen, D.G., Hiddemann, W. and Behre, G. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 101: 270-277, 2003.
32. Vomastek, T., Schaeffer, H.J., Tarcsafalvi, A., Smolkin, M.E., Bissonette, E.A. and Weber, M.J. Modular construction of a signaling scaffold: MORG1 interacts with components of the ERK cascade and links ERK signaling to specific agonists. Proc. Natl. Acad. Sci. USA. 101: 6981-6986, 2004.
33. Wiemels, J.L., Xiao, Z., Buffler, P.A., Maia, A.T., Ma, X., Dicks, B.M., Smith, M.T., Zhang, L., Feusner, J., Wiencke, J., Pritchard-Jones, K., Kempski, H. and Greaves, M. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 99: 3801-3805, 2002.